MedImmune, which already markets Synagis to prevent respiratory syncytial virus in high-risk infants, made another investment in the RSV space by signing a $112 million deal to develop small-molecule compounds discovered by Australian company Biota Holdings Ltd. (BioWorld Today)

MedImmune, which already markets Synagis to prevent respiratory syncytial virus in high-risk infants, made another investment in the RSV space by signing a $112 million deal to develop small-molecule compounds discovered by Australian company Biota Holdings Ltd. (BioWorld Today)